Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes

Eun Young Lee, Myung Sook Shim, Mi Jin Kim, Sae Yong Hong, Young Goo Shin, Choon Hee Chung

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

VEGF expressed in glomerular podocytes, is known to increase vascular permeability to macromolecules. Angiotensin II can stimulate the release of VEGF, and the protective effects of angiotensin II antagonist against diabetic glomerular injury suggest that the angiotensin II-induced VEGF is an important pathogenetic mechanism in the development of proteinuria during diabetic nephropathy although this mechanism is not fully understood. In this study, the changes of VEGF expression was examined in the experimental diabetic nephropathy to determine whether these changes were modified by renoprotective intervention by blockers of angiotensin II receptors. The streptozotocin-induced diabetic rats were treated with L-158,809, a blocker of angiotensin II receptors, for 12 weeks. Age-matched rats with L-158,809 served as controls. RT-PCR and immunohistochemistry were used to assess and quantify gene and protein expression of VEGF. A progressive increase in urinary protein excretion was observed in diabetic rats. Glomerular VEGF expression was significantly higher in diabetic rats than in the control groups, with a significant reduction in glomerular VEGF expression and proteinuria in L-158,809-treated diabetic rats. VEGF mRNA was also significantly higher in diabetic kidneys than in the control groups, with a significant reduction in VEGF mRNA in L-158,809-treated diabetic kidneys. These results demonstrates that VEGF expression is significantly increased in diabetic podocytes, and angiotensin II receptor antagonist attenuated these changes in VEGF expression and prevented the development of proteinuria in vivo. Attenuation of increased VEGF expression in podocytes could contribute to the renoprotective effects of angiotensin II receptor antagonists in diabetic nephropathy.

Original languageEnglish
Pages (from-to)65-70
Number of pages6
JournalExperimental and Molecular Medicine
Volume36
Issue number1
DOIs
Publication statusPublished - 2004 Feb 29

Fingerprint

Podocytes
Angiotensin Receptor Antagonists
Vascular Endothelial Growth Factor A
Rats
Diabetic Nephropathies
Proteinuria
Angiotensin II
Kidney
Control Groups
Messenger RNA
Capillary Permeability
Streptozocin
Macromolecules
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Lee, Eun Young ; Shim, Myung Sook ; Kim, Mi Jin ; Hong, Sae Yong ; Shin, Young Goo ; Chung, Choon Hee. / Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. In: Experimental and Molecular Medicine. 2004 ; Vol. 36, No. 1. pp. 65-70.
@article{51ed7a5c17584586a1685e241a307181,
title = "Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes",
abstract = "VEGF expressed in glomerular podocytes, is known to increase vascular permeability to macromolecules. Angiotensin II can stimulate the release of VEGF, and the protective effects of angiotensin II antagonist against diabetic glomerular injury suggest that the angiotensin II-induced VEGF is an important pathogenetic mechanism in the development of proteinuria during diabetic nephropathy although this mechanism is not fully understood. In this study, the changes of VEGF expression was examined in the experimental diabetic nephropathy to determine whether these changes were modified by renoprotective intervention by blockers of angiotensin II receptors. The streptozotocin-induced diabetic rats were treated with L-158,809, a blocker of angiotensin II receptors, for 12 weeks. Age-matched rats with L-158,809 served as controls. RT-PCR and immunohistochemistry were used to assess and quantify gene and protein expression of VEGF. A progressive increase in urinary protein excretion was observed in diabetic rats. Glomerular VEGF expression was significantly higher in diabetic rats than in the control groups, with a significant reduction in glomerular VEGF expression and proteinuria in L-158,809-treated diabetic rats. VEGF mRNA was also significantly higher in diabetic kidneys than in the control groups, with a significant reduction in VEGF mRNA in L-158,809-treated diabetic kidneys. These results demonstrates that VEGF expression is significantly increased in diabetic podocytes, and angiotensin II receptor antagonist attenuated these changes in VEGF expression and prevented the development of proteinuria in vivo. Attenuation of increased VEGF expression in podocytes could contribute to the renoprotective effects of angiotensin II receptor antagonists in diabetic nephropathy.",
author = "Lee, {Eun Young} and Shim, {Myung Sook} and Kim, {Mi Jin} and Hong, {Sae Yong} and Shin, {Young Goo} and Chung, {Choon Hee}",
year = "2004",
month = "2",
day = "29",
doi = "10.1038/emm.2004.9",
language = "English",
volume = "36",
pages = "65--70",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "1",

}

Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. / Lee, Eun Young; Shim, Myung Sook; Kim, Mi Jin; Hong, Sae Yong; Shin, Young Goo; Chung, Choon Hee.

In: Experimental and Molecular Medicine, Vol. 36, No. 1, 29.02.2004, p. 65-70.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes

AU - Lee, Eun Young

AU - Shim, Myung Sook

AU - Kim, Mi Jin

AU - Hong, Sae Yong

AU - Shin, Young Goo

AU - Chung, Choon Hee

PY - 2004/2/29

Y1 - 2004/2/29

N2 - VEGF expressed in glomerular podocytes, is known to increase vascular permeability to macromolecules. Angiotensin II can stimulate the release of VEGF, and the protective effects of angiotensin II antagonist against diabetic glomerular injury suggest that the angiotensin II-induced VEGF is an important pathogenetic mechanism in the development of proteinuria during diabetic nephropathy although this mechanism is not fully understood. In this study, the changes of VEGF expression was examined in the experimental diabetic nephropathy to determine whether these changes were modified by renoprotective intervention by blockers of angiotensin II receptors. The streptozotocin-induced diabetic rats were treated with L-158,809, a blocker of angiotensin II receptors, for 12 weeks. Age-matched rats with L-158,809 served as controls. RT-PCR and immunohistochemistry were used to assess and quantify gene and protein expression of VEGF. A progressive increase in urinary protein excretion was observed in diabetic rats. Glomerular VEGF expression was significantly higher in diabetic rats than in the control groups, with a significant reduction in glomerular VEGF expression and proteinuria in L-158,809-treated diabetic rats. VEGF mRNA was also significantly higher in diabetic kidneys than in the control groups, with a significant reduction in VEGF mRNA in L-158,809-treated diabetic kidneys. These results demonstrates that VEGF expression is significantly increased in diabetic podocytes, and angiotensin II receptor antagonist attenuated these changes in VEGF expression and prevented the development of proteinuria in vivo. Attenuation of increased VEGF expression in podocytes could contribute to the renoprotective effects of angiotensin II receptor antagonists in diabetic nephropathy.

AB - VEGF expressed in glomerular podocytes, is known to increase vascular permeability to macromolecules. Angiotensin II can stimulate the release of VEGF, and the protective effects of angiotensin II antagonist against diabetic glomerular injury suggest that the angiotensin II-induced VEGF is an important pathogenetic mechanism in the development of proteinuria during diabetic nephropathy although this mechanism is not fully understood. In this study, the changes of VEGF expression was examined in the experimental diabetic nephropathy to determine whether these changes were modified by renoprotective intervention by blockers of angiotensin II receptors. The streptozotocin-induced diabetic rats were treated with L-158,809, a blocker of angiotensin II receptors, for 12 weeks. Age-matched rats with L-158,809 served as controls. RT-PCR and immunohistochemistry were used to assess and quantify gene and protein expression of VEGF. A progressive increase in urinary protein excretion was observed in diabetic rats. Glomerular VEGF expression was significantly higher in diabetic rats than in the control groups, with a significant reduction in glomerular VEGF expression and proteinuria in L-158,809-treated diabetic rats. VEGF mRNA was also significantly higher in diabetic kidneys than in the control groups, with a significant reduction in VEGF mRNA in L-158,809-treated diabetic kidneys. These results demonstrates that VEGF expression is significantly increased in diabetic podocytes, and angiotensin II receptor antagonist attenuated these changes in VEGF expression and prevented the development of proteinuria in vivo. Attenuation of increased VEGF expression in podocytes could contribute to the renoprotective effects of angiotensin II receptor antagonists in diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=1642358301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642358301&partnerID=8YFLogxK

U2 - 10.1038/emm.2004.9

DO - 10.1038/emm.2004.9

M3 - Article

VL - 36

SP - 65

EP - 70

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 1

ER -